Basit Chaudhry, MD, PhD, founder of Tuple Health, explains why it's important to evaluate the adequacy of the novel therapy adjustment under the Oncology Care Model (OCM).
Basit Chaudhry, MD, PhD, founder of Tuple Health, explains why it's important to evaluate the adequacy of the novel therapy adjustment under the Oncology Care Model (OCM).
Transcript
Why is it important to evaluate the adequacy of the novel therapy adjustment under the OCM as more of these therapies continue to enter the market?
Oncology is CMMI’s [Center for Medicare and Medicaid Innovation’s] first foray into a large-scale subspecialty model. One of the things that makes oncology so unique is that it’s so dynamic. The nature of the therapy literally changes month by month, and this is a key reason why we’ve made so much progress in terms of improving outcomes for patients. At the same time, it really does create tensions on how to think about to build a payment model. For payment and looking at value, ideally, you’d something that’s relatively stable that, for instance, allows you to predict the price of an episode better. But, if you’re constantly changing the inputs that physicians and practices are utilizing, then that makes the rest of this difficult.
I think in principle, the novel therapy adjustment was an interesting idea in trying to balance these 2 things. How do you balance the notion of needing to go to value in a field that’s constantly changing? I think in terms of its implementation, there’s some tensions there that have been lacking. So, there’s still a lot of work to be done there. But I think the impetus behind it, I think, is how do you maintain, essentially, innovation and therapy while still being able to construct value and to be able to predict that and stabilize it is a very big challenge.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More